摘要
近年来,靶向针对HCV生活周期中病毒蛋白的直接抗病毒药物(DAA)的研究得到了迅速发展,但是各种DAA均存在特异的耐药位点,且与基因型/亚型相关。依据DAA的作用机制概述各类药物的耐药位点及其对治疗方案的影响,指出某些天然变异位点的存在使得部分HCV基因亚型患者在治疗中耐药,故在治疗前需要谨慎评估以选择适当方案;而对于既往干扰素治疗失败的患者,如需联合DAA或直接采用无干扰素的DAA联合治疗方案,还需要就预存耐药等问题作进一步研究。
In recent years, direct -acting antiviral agent （DAA） that target specific enzymes in the life cycle of hepatitis C virus （HCV） have been developed rapidly. However, there are specific resistance - related mutation sites for DAA, which is associated with the gene types/subtypes of HCV. This article describes the resistance - related mutation sites for DAA and their impacts on the treatment regimen according to the mechanism of action of DAA. It is pointed out that some natural nmtation sites lead to drug resistance in the treatment for patients with some HCV subtypes, so careful evaluation is needed before treatment to determine the appropriate regimen. For patients experiencing failure in the previous interferon therapy, the pre - existing drug resistance should be studied if DAA in combination with the therapy or interferonfree DAA therapies are to be used.
出处
《临床肝胆病杂志》
CAS
2015年第11期1807-1812,共6页
Journal of Clinical Hepatology
基金
十二五国家科技重大专项(2013ZX10002002-006
2012ZX10002003)
首都临床特色应用研究与成果推广(Z151100004015181)
首都卫生发展科研专项(首发2011-2018-08)
(感染病科)国家临床重点专科建设项目(WJWYA-2014-007)
北京佑安医院肝病艾滋病基金(20150205)
重大传染病防治协同创新项目(PXM2015_014226_000058)
关键词
肝炎病毒属
抗病毒药
多药耐药相关蛋白质类
hepacivirus
antiviral agents
muhidrug resistance - associated proteins
